NASDAQ:INZY Inozyme Pharma (INZY) Stock Price, News & Analysis $5.83 +0.04 (+0.69%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$5.70▼$5.9650-Day Range$4.37▼$5.7952-Week Range$2.69▼$7.80Volume189,757 shsAverage Volume498,596 shsMarket Capitalization$360.64 millionP/E RatioN/ADividend YieldN/APrice Target$16.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Inozyme Pharma alerts: Email Address Inozyme Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside174.4% Upside$16.00 Price TargetShort InterestBearish10.23% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.62Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.59) to ($1.61) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.29 out of 5 starsMedical Sector777th out of 936 stocksPharmaceutical Preparations Industry360th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingInozyme Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageInozyme Pharma has only been the subject of 4 research reports in the past 90 days.Read more about Inozyme Pharma's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted10.23% of the float of Inozyme Pharma has been sold short.Short Interest Ratio / Days to CoverInozyme Pharma has a short interest ratio ("days to cover") of 11.5, which indicates bearish sentiment.Change versus previous monthShort interest in Inozyme Pharma has recently increased by 3.15%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldInozyme Pharma does not currently pay a dividend.Dividend GrowthInozyme Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INZY. Previous Next 2.6 News and Social Media Coverage News SentimentInozyme Pharma has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Inozyme Pharma this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for INZY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Inozyme Pharma to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inozyme Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders11.19% of the stock of Inozyme Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.30% of the stock of Inozyme Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Inozyme Pharma's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Inozyme Pharma are expected to decrease in the coming year, from ($1.59) to ($1.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inozyme Pharma is -4.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inozyme Pharma is -4.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInozyme Pharma has a P/B Ratio of 2.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Inozyme Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIHow a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…Click now to see for yourself what $0.25 Cent Trades is all about About Inozyme Pharma Stock (NASDAQ:INZY)Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Read More INZY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INZY Stock News HeadlinesJuly 25 at 8:30 AM | globenewswire.comInozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel FunctionJuly 17, 2024 | americanbankingnews.comAnalyzing Inozyme Pharma (NASDAQ:INZY) and Iterum Therapeutics (NASDAQ:ITRM)July 26, 2024 | DTI (Ad)How to build the ultimate dividend portfolioThere’s a free dividend workshop that shows how anyone can build the ultimate dividend workshop in 3 basic steps? PLUS: You’ll get the names and tickers of the Best Dividend Stocks for FREE… This way, by the time you finish the workshop you’ll be fully equipped with the knowledge to start unlocking dividend checks for yourself… Over and over again.July 2, 2024 | globenewswire.comInozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 DeficiencyJune 21, 2024 | globenewswire.comInozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children's Bone Health (ICCBH)May 23, 2024 | globenewswire.comInozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical ConferencesMay 8, 2024 | finanznachrichten.deInozyme Pharma Inc.: Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business HighlightsMay 8, 2024 | msn.comInozyme Pharma GAAP EPS of -$0.38 beats by $0.02July 26, 2024 | DTI (Ad)How to build the ultimate dividend portfolioThere’s a free dividend workshop that shows how anyone can build the ultimate dividend workshop in 3 basic steps? PLUS: You’ll get the names and tickers of the Best Dividend Stocks for FREE… This way, by the time you finish the workshop you’ll be fully equipped with the knowledge to start unlocking dividend checks for yourself… Over and over again.May 8, 2024 | markets.businessinsider.comInozyme Pharma Buy Rating Affirmed on Strong Trial Results and Robust Pipeline ProspectsMay 8, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Esperion (ESPR) and Madrigal Pharmaceuticals (MDGL)May 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT) and Inozyme Pharma (INZY)May 8, 2024 | globenewswire.comInozyme Pharma to Participate at the Bank of America Securities 2024 Health Care ConferenceMay 7, 2024 | investorplace.comINZY Stock Earnings: Inozyme Pharma Misses EPS for Q1 2024May 7, 2024 | globenewswire.comInozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business HighlightsMay 3, 2024 | globenewswire.comInozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 9, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Inozyme Pharma (INZY), Moderna (MRNA)April 8, 2024 | markets.businessinsider.comInozyme Reports Positive Topline Data From Phase 1/2 Study Of INZ-701; Stock UpSee More Headlines Receive INZY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inozyme Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:INZY CUSIPN/A CIK1693011 Webwww.inozyme.com Phone857-330-4340FaxN/AEmployees59Year FoundedN/APrice Target and Rating Average Stock Price Target$16.00 High Stock Price Target$23.00 Low Stock Price Target$14.00 Potential Upside/Downside+174.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,170,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-58.74% Return on Assets-42.00% Debt Debt-to-Equity Ratio0.38 Current Ratio14.05 Quick Ratio14.05 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.27 per share Price / Book2.57Miscellaneous Outstanding Shares61,860,000Free Float54,934,000Market Cap$360.64 million OptionableOptionable Beta1.53 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Douglas A. Treco Ph.D. (Age 66)CEO & Chairman Comp: $591.88kMr. Axel Bolte M.B.A. (Age 52)M.Sc., Co-Founder, Senior Advisor & Director Comp: $1.16MMr. Sanjay S. Subramanian M.B.A. (Age 47)M.S., Senior VP, CFO, Principal Accounting Officer & Corporate Secretary Comp: $626.23kDr. Matthew Winton Ph.D. (Age 46)Senior VP & COO Comp: $526.43kDr. Demetrios Braddock M.D.Ph.D., Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board ObserverDr. Soojin Kim Ph.D.Senior VP & Chief Technical Operations OfficerDr. David Thompson M.A.M.S., Ph.D., Senior VP, Chief Scientific Officer & Chief Development OfficerMr. Stefan RileyDirector of Investor RelationsMs. Gayle GirondaSenior VP & Chief People OfficerDr. Yves Sabbagh Ph.D.Chairman of Scientific Advisory Board & Senior VPMore ExecutivesKey CompetitorsFoghorn TherapeuticsNASDAQ:FHTXZIOPHARM OncologyNASDAQ:ZIOPStemline TherapeuticsNASDAQ:STMLEagle PharmaceuticalsNASDAQ:EGRXDay One BiopharmaceuticalsNASDAQ:DAWNView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 26,464 shares on 7/26/2024Ownership: 0.309%Values First Advisors Inc.Bought 17,067 shares on 7/19/2024Ownership: 0.028%Kennedy Capital Management LLCBought 150,120 shares on 5/16/2024Ownership: 0.708%California State Teachers Retirement SystemSold 3,059 shares on 5/16/2024Ownership: 0.008%Affinity Asset Advisors LLCBought 756,717 shares on 5/15/2024Ownership: 4.272%View All Insider TransactionsView All Institutional Transactions INZY Stock Analysis - Frequently Asked Questions How have INZY shares performed this year? Inozyme Pharma's stock was trading at $4.26 at the beginning of the year. Since then, INZY stock has increased by 36.9% and is now trading at $5.83. View the best growth stocks for 2024 here. How were Inozyme Pharma's earnings last quarter? Inozyme Pharma, Inc. (NASDAQ:INZY) announced its quarterly earnings results on Tuesday, May, 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by $0.03. When did Inozyme Pharma IPO? Inozyme Pharma (INZY) raised $75 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Inozyme Pharma's major shareholders? Inozyme Pharma's top institutional shareholders include Bank of New York Mellon Corp (0.31%) and Values First Advisors Inc. (0.03%). Insiders that own company stock include Longitude Capital Partners Iii, Robert Lorne Hopfner, Pivotal Bioventure Partners Fu, Axel Bolte, Henric Bjorn Bjarke and Douglas A Treco. View institutional ownership trends. How do I buy shares of Inozyme Pharma? Shares of INZY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Inozyme Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Inozyme Pharma investors own include Procter & Gamble (PG), RTX (RTX), Cisco Systems (CSCO), CSX (CSX), CVS Health (CVS) and Home Depot (HD). This page (NASDAQ:INZY) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inozyme Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inozyme Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INZY Stock Alerts